February 2018

New Product - Trumenba

Trumenba (meningococcal group B vaccine) prevents meningococcal serogroup B disease by inducing broadly protective bactericidal antibody responses against epidemiologically diverse serogroup B strains. Trumenba is indicated in individuals 10 years and older for active immunisation to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B. Trumenba is contraindicated with severe allergic reaction (e.g. anaphylaxis) after any previous dose of Trumenba or to any component of this vaccine. Trumenba suspension for injection is supplied as a single 0.5 mL prefilled syringe.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia┬áPty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629